Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anoctamin 1 (ANO1) is a calcium-activated chloride channel overexpressed in non-small cell lung cancer (NSCLC).
• ANO1 is a potential therapeutic target for NSCLC, but its exact role in cancer progression is unclear.
• Existing ANO1 inhibitors affect both channel activity and protein levels, complicating mechanistic studies.

Purpose of the Study:

• To identify compounds that specifically reduce ANO1 protein levels.
• To elucidate the anticancer mechanism of verteporfin in NSCLC cells.
• To determine if ANO1 protein down-regulation is the primary driver of verteporfin's anti-NSCLC effects.

Main Methods:

• High-throughput screening to identify ANO1 protein level reducers.
• In vitro assays to assess ANO1 channel activity, chloride secretion, and intracellular calcium mobilization.
• Molecular docking studies to predict verteporfin binding sites on ANO1.
• Western blotting and qRT-PCR to analyze protein and mRNA expression.
• Cell viability assays and apoptosis marker analysis (caspase-3, PARP-1 cleavage).

Main Results:

• Verteporfin was identified as a compound that reduces ANO1 protein levels (~300 nM IC50) without inhibiting ANO1 channel activity.
• Verteporfin selectively decreased ANO1 protein and mRNA levels, impacting the EGFR-STAT3 pathway.
• Verteporfin reduced viability and induced apoptosis in ANO1-expressing NSCLC cells, including gefitinib-resistant lines.
• Verteporfin did not affect P2Y receptor signaling, CFTR, or hERG channel activity.

Conclusions:

• Verteporfin exerts its anticancer effects in NSCLC by down-regulating ANO1 protein levels.
• Targeting ANO1 protein expression represents a promising therapeutic strategy for NSCLC.
• Verteporfin's mechanism is distinct from direct ANO1 channel inhibition.